http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
-
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
-
JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE
-
SkinMedica® Launches Even & Correct
-
AbbVie (ABBV), Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
-
AbbVie (ABBV), Immunome (IMNM) Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
-
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
-
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
-
AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
-
AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
AbbVie (ABBV) Announces FDA Approval of VRAYLAR
-
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
-
AbbVie (ABBV) Submits sNDA to U.S. FDA to Support New Indication of LINZESS for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
-
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
-
AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year
-
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
-
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
-
AbbVie (ABBV) Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
-
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
-
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
-
CIBC Launches 5 New CDRs (“Canadian Depositary Receipts”) on the NEO Exchange
-
AbbVie to Present at the Evercore ISI HealthCONx Conference
-
AbbVie (ABBV) Announces EU Approval of SKYRIZI for Moderate to Severe Active Crohn's Disease
-
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
-
AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting
-
AbbVie to Present at the Piper Sandler Healthcare Conference
-
AbbVie (ABBV) Announces FDA Accepts for Priority Review BLA for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
-
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
-
Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet
-
AbbVie to Present at the Wolfe Research Healthcare Conference
-
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
-
AbbVie (ABBV) Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of POAF in Cardiac Surgery Patients
-
AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Pat
-
Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness
-
Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
-
Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL
-
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL
-
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (L
-
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL
-
AbbVie Reports Third-Quarter 2022 Financial Results
-
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting
-
AbbVie (ABBV) Announces Sixth RINVOQ FDA Approval in the US
-
RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval
-
AbbVie (ABBV) Acquires DJS Antibodies
-
AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline
-
AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire
-
AbbVie to Host Third-Quarter 2022 Earnings Conference Call
-
AbbVie (ABBV) Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week
-
AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022
